RXRX vs PVLA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
PVLA Captures Institutional Edge (2โ1 Pillars ยท 4โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Palvella Therapeutics, Inc. Common Stock (PVLA) driven by superior Momentum & Technical, Options & Structure while RXRX counters with relative strength in Growth & Margin. Fundamentally, RXRX trades at N/M Forward P/E with -734.2% operating margin (+258.5% YoY revenue) versus PVLA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, RXRX sits in BREAKDOWN (61st %ile IV; Dealer Gamma Walls on Pro) against PVLA sits in CONSOLIDATION (2nd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | RXRX Revenue | PVLA Revenue | RXRX Op. Margin | PVLA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $30M | N/A | -113.1% | PVLA |
| FY2019 | $0M | $40M | -2692.6% | -62.2% | PVLA |
| FY2020 | $0M | $30M | -2135.7% | -115.7% | PVLA |
| FY2021 | $10M | $30M | -1795.8% | -165.0% | PVLA |
| FY2022 | $40M | $30M | -616.7% | -167.8% | PVLA |
| FY2023 | $40M | $40M | -785.3% | -27.7% | PVLA |
| FY2024 | $60M | N/A | -814.1% | N/A | RXRX |
| FY2025 | $70M | N/A | -867.9% | N/A | RXRX |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | RXRX | PVLA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.1B | $2.2B | Larger Scale | PVLA |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +258.5% | +0.0% | Higher Growth | RXRX |
| Operating Margin (TTM) Profitability | -734.2% | 0.0% | Higher Margin | PVLA |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -48.7% | -63.4% | Higher ROE | RXRX |
| 52-Week Range Position Momentum | 6% ($3โ$5) | 68% ($72โ$180) | Stronger Trend | PVLA |
| Beta / 30D Volatility Risk Regime | 3.01ฮฒ ยท 85% Vol | 1.66ฮฒ ยท 75% Vol | Lower Realized Risk | PVLA |
| Unified Institutional Score Composite Signal | 49.5 / 100 (HOLD) | 48.2 / 100 (HOLD) | Higher Composite | RXRX |